Biologics Drug Substance Manufacturing CMO: Market Size & Forecast 2026

Biologic drug substance manufacturing CMOs provide end-to-end services from cell line development through process scale-up to commercial production of biologic active pharmaceutical ingredients. The market encompasses both pure-play contract manufacturers and integrated pharmaceutical companies that offer contract services alongside their proprietary product portfolios. Because no government statistical agency tracks this sub-sector separately, market sizing relies on private analyst estimates that vary by scope definition.

• •Estimated global market size of approximately $20 billion in 2025, based on industry analyst assessments
• •Scope typically includes upstream processing of mAbs, vaccines, recombinant proteins, and cell and gene therapy products
• •NAICS 325414 in the U.S. aggregates all biologic product manufacturing without distinguishing between in-house and outsourced production

The biologics drug pipeline has expanded substantially, with monoclonal antibodies and cell and gene therapies representing a growing share of pharmaceutical R&D investments. Pharmaceutical companies increasingly prefer to outsource manufacturing rather than build and staff expensive dedicated facilities, allowing them to deploy capital toward research and commercialization. The technical complexity of biologic production, requiring specialized bioreactor systems and controlled environments, makes contracted expertise economically attractive.

• •Outsourcing reduces the need for heavy capital investment in manufacturing infrastructure, especially for smaller biotechs without production capabilities
• •Post-pandemic supply chain diversification has led companies to broaden their manufacturing partner networks
• •Cell and gene therapies and personalized medicine require specialized manufacturing platforms that many developers lack internally

The market divides primarily by product type, with monoclonal antibody manufacturing representing the largest segment, followed by recombinant proteins, vaccines, and the rapidly growing cell and gene therapy sector. Geographically, North America and Europe have historically dominated due to their concentration of biopharmaceutical developers, while the Asia-Pacific region has gained share driven by cost competitiveness and expanding local capacity. China and South Korea in particular have developed significant biologic manufacturing footprints.

• •Monoclonal antibodies account for the largest share of biologic drug substance manufacturing volume
• •Asia-Pacific markets have grown faster than other regions, supported by government biotech investments and cost advantages
• •The cell and gene therapy segment, while smaller in revenue, is among the fastest-growing segments

Who are the notable companies in the industry?

The competitive field features large diversified CMOs with integrated biologic capabilities alongside specialized contract manufacturers focused on particular modalities. Several major pharmaceutical companies operate contract manufacturing divisions that serve third-party clients in addition to internal production needs. Market concentration is moderate, with the top tier comprising a mix of publicly traded CMOs, pharmaceutical manufacturing subsidiaries, and regional specialists.

• •Lonza Group, headquartered in Switzerland, operates large-scale biologic manufacturing facilities across multiple continents
• •Thermo Fisher Scientific provides biologics contract development and manufacturing through its Patheon network with significant U.S. and European presence
• •WuXi Biologics, based in China, has become one of the world's largest biologic CDMOs by capacity, with facilities in China, Ireland, Germany, and the United States

What are the recent trends and outlook?

Industry participants are investing heavily in single-use bioreactor technologies to improve flexibility and reduce cross-contamination risks, particularly for smaller batch and personalized therapies. Demand for continuous manufacturing platforms and modular facilities is increasing as companies seek to shorten production timelines. The market is expected to sustain its growth trajectory through the end of the decade as novel biologic modalities enter commercial production and outsourced manufacturing becomes standard practice across the industry.

• •Single-use bioreactor technology adoption continues to accelerate, reducing facility changeover times and contamination risks
• •The cell and gene therapy segment is driving new investment in specialized manufacturing capacity
• •Consolidation through mergers and acquisitions has been a notable feature as CMOs seek to broaden their service portfolios